Agenus (AGEN) is a development-stage biotechnology company specializing in vaccines. In September 2012 the number of Seeking Alpha articles spiked to 6, as can be seen on the Seeking Alpha Agenus page. In Q2 2013 there was only one Seeking Alpha article, and before 2012 the prior article was in July 2010.
So what is the excitement about, and should you buy Agenus?
Note first that Agenus is a small-cap stock, and can be subject to large price swings at relatively low trading volumes.
Agenus has no therapy approved by the FDA. Its value has to be based on future revenue and earnings from commercialized therapies. Agenus has sold rights to some of its IP to several other...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: